PSTI Pluristem Therapeutics Inc.

3.82
+0.04  (+1%)
Previous Close 3.78
Open 3.78
Price To Book 3.41
Market Cap 60,018,144
Shares 15,711,556
Volume 37,272
Short Ratio
Av. Daily Volume 53,489
Stock charts supplied by TradingView

NewsSee all news

  1. Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

    HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced

  2. Pluristem Therapeutics CEO Issues Shareholder Update

    HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an

  3. RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare

    RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020 HAIFA, Israel, Nov. 04, 2019 (GLOBE

  4. Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

    PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantationData from 1st and 2nd cohorts of hematological

  5. Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

    HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 EU data due 2Q 2020; US data due 1H 2021.
PLX-PAD (stem cells)
Critical limb ischemia (CLI)
Phase 2 data released June 12, 2018 - primary endpoint met.
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 1 DSMB approval given to continue to the final cohort - March 12, 2019.
PLX-R18
Incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT)
Phase 3 data due 2H 2020.
PLX-PAD
Muscle injury following hip fracture

Latest News

  1. Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

    HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced

  2. Pluristem Therapeutics CEO Issues Shareholder Update

    HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an

  3. RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare

    RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020 HAIFA, Israel, Nov. 04, 2019 (GLOBE

  4. Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

    PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantationData from 1st and 2nd cohorts of hematological

  5. Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

    HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information